Browse News

Found 2,374 articles

• ClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery

  5/24/2023

  ClearPoint Neuro, Inc. (NASDAQ: CLPT) a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it has entered into a multi-year license agreement with UCB (EURONEXT BRUSSELS: UCB), a global biopharmaceutical leader, to partner on drug delivery platforms for UCB’s gene therapy portfolio.

• UCB and Veeva Collaborate to Advance the Patient Experience in Clinical Trials

  5/23/2023

  Veeva Systems (NYSE: VEEV) and UCB , a global biopharmaceutical company, today announced a collaboration that will focus on technology-driven solutions aimed at improving the patient experience and trial efficiency.

• G1 Therapeutics Announces Appointment of Monica Thomas as General Counsel

  5/22/2023

  G1 Therapeutics, Inc., a commercial-stage oncology company, announced the appointment of Monica Thomas as its General Counsel and Chief Compliance Officer.

• Alcami Appoints Laurent Boer as General Manager of Biostorage and Pharmaceutical Support Services.

  5/16/2023

  Alcami Corporation, a leading contract development and manufacturing organization, announced the appointment of Laurent Boer to the newly created position of General Manager, Biostorage and Pharma Services.

• Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2023 Financial Results

  5/11/2023

  Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update and reported financial results for the first quarter 2023.

• Curis Provides First Quarter 2023 Business Update

  5/4/2023

  Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, reported its business update and financial results for the first quarter ended March 31, 2023.

• Biophytis Strengthens its Management Team

  5/2/2023

  Biophytis SA announces the strengthening of its management team with the appointment of Chiara Baccelli to the newly created position of Director of Pharmaceutical Operations and Quality Assurance and the upcoming arrival of Nicolas Fellmann as Chief Financial Officer as of 22 May 2022.

• Huma and UCB partner to provide digital health solution to improve management of the rare disease, Myasthenia gravis

  4/26/2023

  Huma Therapeutics and UCB are partnering to offer a digital technology solution to help patients with the rare disease, Myasthenia gravis, better understand and manage their condition with the support of their clinician.

• UCB Showcases Strength and Depth of Neurology Portfolio at 75th American Academy of Neurology (AAN) Annual Meeting

  4/20/2023

  UCB will showcase data from its expansive and innovative neurology portfolio at the 75th American Academy of Neurology (AAN) Annual Meeting, April 22-27, 2023.

• UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance

  4/17/2023

  UCB (Euronext: UCB), a global biopharmaceutical company, today announced the U.S. Drug Enforcement Administration (DEA) has published a final rule stating that FINTEPLA oral solution is no longer subject to the Controlled Substances Act (CSA).

• Nona Biosciences Enters into Collaboration Agreement with ExeVir Bio

  4/6/2023

  Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge technology innovation and provider of integrated solutions from "Idea to IND", announced it has entered into a collaboration agreement with ExeVir Bio.

• Inozyme Pharma Reports Full Year 2022 Financial Results and Provides Business Highlights

  3/22/2023

  Inozyme Pharma, Inc today reported financial results for the full year ended December 31, 2022, and provided recent business highlights.

• Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks

  3/18/2023

  UCB, a global biopharmaceutical company, announced detailed positive results from two Phase 3 studies evaluating the efficacy and safety of bimekizumab in the treatment of adults with moderate to severe hidradenitis suppurativa.

• UCB to Present Eight Bimekizumab Abstracts at AAD 2023 with Results from Studies in Psoriasis, Psoriatic Arthritis, and Hidradenitis Suppurativa

  3/16/2023

  UCB, a global biopharmaceutical company, today announced that it will present eight bimekizumab abstracts across a range of IL-17 mediated diseases.

• Aitia and UCB Announce Strategic Drug Discovery Collaboration in Huntington's Disease

  3/15/2023

  UCB, a global biopharmaceutical company, and Aitia, the leader in the application of Causal AI and "Digital Twins" to discover and develop new drugs, today announced an early drug discovery collaboration focused on the discovery and validation of novel drug targets and drug candidates for Huntington's disease.

• Switch Therapeutics Launches with $52 Million to Advance First-of-its-Kind RNAi Technology

  3/14/2023

  Switch Therapeutics today announced its launch following $52 million of financing.

• Newron Announces 2022 Financial Results and Provides Outlook For 2023

  3/14/2023

  Newron Pharmaceuticals S.p.A. today announced its financial results and operational highlights for the business year ended December 31, 2022, and provided an outlook for 2023.

• ExeVir Bio and VIB Announce Data on a New Therapy for Prevention and Treatment for COVID-19

  3/13/2023

  ExeVir Bio announced the publication of a pre-print paper by De Cae et al., entitled “Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spike”.

• Iktos raises € 15.5m Series A round to expand its artificial intelligence-based drug discovery technologies and solutions

  3/9/2023

  Iktos announces the closing of a € 15.5m Series A financing co-led by new investors M Ventures and Debiopharm Innovation Fund with participation from Omnes Capital.

• Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement

  3/7/2023

  Covant Therapeutics, an innovative covalent drug discovery company incubated by Roivant Sciences, announced the formation of its Scientific Advisory Board.